1. Home >
  2. M&A >
  3. PIPE >
  4. United States >
  5. California >
  6. Aisling Capital Invests In Spruce Biosciences

Investment Summary

Aisling Capital Invests In Spruce Biosciences

On February 19, 2020, private equity firm Aisling Capital invested in life science company Spruce Biosciences

Investment Highlights
  • This is Aisling Capital’s 40th transaction in the Life Science sector.
  • This is Aisling Capital’s 49th transaction in the United States.
  • This is Aisling Capital’s 14th transaction in California.

Investment Summary
Date 2020-02-19
Target Spruce Biosciences
Sector Life Science
Investor(s) Aisling Capital
Deal Type PIPE

Target

Spruce Biosciences

South San Francisco, California, United States
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with a significant unmet medical need. The company develops tildacerfont, a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. Spruce Biosciences was founded in 2014 and is based in South San Francisco, California.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Aisling Capital

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 1.8B USD
Size Large
Type Sector Focused
DESCRIPTION

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.

DEAL STATS #
Overall 52 of 56
Sector: Life Science M&A 40 of 42
Type: PIPE M&A Deals 12 of 12
State: California M&A 14 of 15
Country: United States M&A 49 of 52
Year: 2020 M&A 3 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-08 Medical Knowledge Group

New York, New York, United States

Medical Knowledge Group address the business needs of biopharmaceutical companies through the provision of network-mapping analytics, patient-finding analytics, and multi-channel marketing solutions. Medical Knowledge Group was formed in 2004 and is based in New York, New York.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-19 Harmony

Plymouth Meeting, Pennsylvania, United States

Harmony is a biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders. Harmony was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Sell -
Mergr

Solution for

Product

Company

Legal